Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer

Abstract

Several recent studies have revealed that microRNAs (miRNAs) have a role in carcinogenesis and cancer development, and that it is stably detectable in plasma/serum. The aim of this study was to test whether miR-483-3p as well as miR-21 could be plasma biomarkers for PDAC. The plasma samples were obtained from three groups including 32 pancreatic ductal adenocarcinoma (PDAC) patients, 12 patients with intraductal papillary mucinous neoplasm (IPMN) patients and 30 healthy controls (HC). We evaluated the plasma miR-483-3p and miR-21 expression level by quantitative RT-PCR. We compared the differences in the plasma level of these miRNAs among the three groups, and investigated the relevance of their plasma expression level to the clinical factors in PDAC. The expressions of miR-483-3p and miR-21 were detected in all examined plasma samples. The plasma expression levels of these miRNAs were significantly higher in PDAC compared to HC (P<0.01). The plasma miR-483-3p expression was significantly higher in PDAC patients than IPMN patients (P<0.05). The plasma miR-21 level was associated with advanced stage (P<0.05), metastasis to lymph node and liver (P<0.01), and shorter survival (P<0.01) of the PDAC patients. Together, these findings suggest that measurement of the plasma miR-483-3p level is useful for discriminating PDAC from IPMN, and that the plasma miR-21 level predicts outcome of PDAC patients.

Altered profile of serum microRNAs in pancreatic cancer‐associated new‐onset diabetes mellitus

“…Elevated expression of miR‐196a , miR‐183, and miR‐21 was found to predict poor survival of pancreatic cancer; miR‐196a and miR‐21 7 appear to be valuable in distinguishing normal pancreas from chronic pancreatitis and cancerous tissues; and miRNA‐21 , miR‐10a , and miR‐1246 mediate chemoresistance of multiple drugs and stemness in pancreatic cancer . Recently, miR‐483‐3p was observed to be significantly higher in the plasma of patients with pancreatic cancer and useful for discriminating pancreatic cancer from intraductal papillary mucinous neoplasm . In a previous study, a set of seven serum miRNAs ( miR‐20a , miR‐21 , miR‐24 , miR‐25 , miR‐99a , miR‐185 , and miR‐191 ) selected by qRT‐PCR effectively discerned pancreatic cancer cases at different disease stages from controls (healthy controls and patients with chronic pancreatitis) .…”

IGF2-derived miR-483 mediated oncofunction by suppressing DLC-1 and associated with colorectal cancer

“…Ng et al showed that miR-92 is significantly elevated in the plasma of CRC patients and might be a potential noninvasive molecular marker for CRC [12]. Accordingly, several subsequent studies have shown that miR-483 can serve as potential biomarkers for various cancers [13–15], however the mechanism by which elevated miR-483 impacts the development of cancer remains unclear. The DLC-1 (Deleted in liver cancer 1) gene was originally discovered as a potential tumor suppressor frequently deleted in hepatocellular carcinoma.…”

Extracellular miRNA-21 as a novel biomarker in glioma: evidence from meta-analysis, clinical validation and experimental investigations

“…Besides in tissues, recent evidence indicates the presence of miR-21 in various types of extracellular fluid, such as plasma [10, 11, 15–33], serum [17, 29, 34–50], CSF [51–56], saliva [32, 57, 58], gastric juice [59], pancreatic juice [60], sputum [61], and pancreatic cyst fluid [62]. Although the diagnostic efficiency of extracellular miR-21 in cancers has been proposed by many researchers, the results are conflicting and inconclusive.…”